Navigation Links
New Antioxidant Drug Shows Promise Against Diabetes
Date:5/23/2008

But more studies on cardiovascular risks needed, report says

FRIDAY, May 23 (HealthDay News) -- A new antioxidant drug shows benefits in the prevention and treatment of diabetes, but more research on possible cardiovascular risks is needed before it is used widely, a new study indicates.

Preliminary results on the drug, succinobucol, have been presented at medical meetings. The full study is published in the May 24 issue of The Lancet.

"There is more data in the article than in the previous presentation, with greater detail on the prevention of diabetes and glycemic [sugar] control," said study author Dr. Jean-Claude Tardif, director of the research center at the Montreal Heart Institute in Canada.

"There are several interesting findings that include a large reduction of new cases of diabetes and also glycemic control in patients who already have diabetes," Tardif said. "But there needs to be confirmation before it is used widely, because there was no effect on clinical endpoints such as heart attack and stroke."

Some confirmation of the drug's effectiveness is expected from a major trial that is nearing completion, Tardif said. Results of that trial should be published "within the next few months," he said.

Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects. In addition to its antioxidant effects, succinobucol also reduces inflammation.

The trial reported in The Lancet included 6,144 people, 37 percent of whom had diabetes and all of whom had been hospitalized for a heart attack or the dangerous heart rhythm problem called unstable angina. For two years, half of the participants took succinobucol daily, while the other half took a placebo. All were taking other drugs, such as cholesterol-lowering statins, beta blockers or ACE inhibitors.

Among the participants who did not have diabetes when the study began, 4.2 percent of those not taking succinobucol developed the disease, compared to 1.64 percent of those taking the drug, a 64 percent risk reduction. For those with diabetes, taking succinobucol provided better blood sugar control than not taking the drug.

Atrial fibrillation, a dangerous heartbeat abnormality, was twice as likely to develop during the trial in those taking succinobucol. There was no difference in the incidence of death, cardiac arrest, heart attack, stroke or other cardiovascular endpoints between those taking or not taking the drug.

"The study results need confirmation before it is used widely, because there was no effect on those clinical endpoints," Tardif said. "But that is true of all the drugs now used in diabetes. There is no evidence that they reduce heart attacks and strokes."

The chief side effect of the drug was diarrhea, reported by 23 percent of those taking it. One in seven of those reporting diarrhea stopped taking succinobucol.

More information

Currently available drugs for diabetes are described by the American Diabetes Association.



SOURCES: Jean-Claude Tardif, M.D., director, Montreal Heart Institute Research Center, Canada; May 23, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Antioxidant Supplements May Raise Womens Skin Cancer Risk
3. New research into plant colors sheds light on antioxidants
4. Antioxidants do not prevent degenerative eye disease
5. Major ORAC Differences Among Top Antioxidant Beverages
6. Grape Consumption Improves Antioxidant Capacity in Humans
7. Snapples New Antioxidant Water and LYTeWater Take Hydration to the Next Level
8. Citrus juice, vitamin C give staying power to green tea antioxidants
9. Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment
10. New Research Confirms Wild Blueberry Antioxidant Power
11. Citrus Juice Gives Boost to Green Tea Antioxidants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Antioxidant Drug Shows Promise Against Diabetes
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC (PER®) ... on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, 2017. ... to have Amy E. Herman present at this year’s conference, her unprecedented knowledge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New York ... participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria in ... that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise in ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. announced ... marketing agreement with development and manufacturing partner Gland ... the terms of this agreement, Breckenridge will market ... the United States . The ... ANDA. The products cover a wide range of ...
(Date:12/5/2016)... 2016  Sharn Anesthesia Inc. announced today that it ... partner for Salter Labs.  The company also received the ... of outstanding sales performance. Salter Labs is ... care, including the market gold standard ECO 2 ... of the Parker Flex-Tip® Endotracheal Tube, which is a ...
Breaking Medicine Technology: